Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 4/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CTSV | O60911 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800072 | 0.85 | CAPN1 (0.34) | CAPN1ICMTCTSBKMT2ACTSL | |
| SCHEMBL22800074 | 0.79 | ICMT (0.35) | CAPN1ICMTKMT2A | |
| SCHEMBL22799771 | 0.75 | JAK3 (0.48) | CTSBCTSLCTSSCTSK | |
| SCHEMBL22799775 | 0.71 | SLC7A5 (0.42) | NOS2 | |
| SCHEMBL22800780 | 0.68 | ICMT (0.37) | CAPN1ICMTALDH1A1KMT2A | |
| SCHEMBL22799633 | 0.68 | LIG1 (0.44) | ALDH1A1KMT2A | |
| SCHEMBL9910861 | 0.68 | CASP1 (0.52) | CTSBALDH1A1CTSLCTSSCTSK | |
| SCHEMBL22799765 | 0.67 | MAPT (0.35) | ALDH1A1 | |
| SCHEMBL22799781 | 0.66 | ALDH1A1 (0.51) | HIF1AALDH1A1KMT2A | |
| SCHEMBL1250617 | 0.65 | MMP9 (0.55) | PYGLCTSBALDH1A1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | CAPN1 3/4885ICMT 4672/4885PYGL 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.